Spatial memory training for people with mild cognitive impairment
Tests a 3-month spatial memory training program in people with mild cognitive impairment.
Key facts
- Who runs it
- Douglas Mental Health University Institute
- Where
- Canada1 site in 1 countryChoose a country to see its sites
- Trial code
- Registry title
- Spatial Memory Training and Cognitive Function
- Status
- Recruiting
- People taking part
- 80 people, planned
- Started
- 15 Jun 2025
- Expected to end
- 30 Dec 2030
- Type of study
- Interventional, 2 groupsOne group gets a placebo (a dummy treatment), for comparison.
- Treatments tested
- SMIP
- Record updated
- 23 July 2025
Who can take part
AI summary
From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.
The trial is looking for people aged 55 or older with a diagnosis of mild cognitive impairment (MCI), a mild memory and thinking problem. It tests a 3-month spatial memory training program.
- Age
- 55 years and older
- Sex
- All sexes
- Disease stage
- Diagnosed mild cognitive impairment (MCI). English or French must be the main language.
- Earlier treatment
- People cannot join if they use or have used antipsychotic medicine, use opioid painkillers or sleep medicines, or had brain surgery or ECT. Antidepressant, anti-anxiety, cholesterol or blood pressure medicine must have been taken for at least 3 months.
Main reasons for not taking part
- Severe depression (GDS score greater than 12), current PTSD, generalized anxiety, insomnia or substance use disorder
- Stroke in the past 5 years or heart disease not stable with medicine
- Current smoker, colour-blindness, or motion sickness with virtual reality
- Brain injury in the last 24 months or general anesthesia in the past year
- Cannot have an MRI scan
The registry criteria, word for word
Show all 21 criteriaShow less
Who can take part
- Age 55 years and above
- Primary language is English or French
- Individuals having received a diagnosis of Mild Cognitive Impairment (MCI)
Who cannot take part
- Self-reported having either of the following:; Current post-traumatic stress disorder and/or generalized anxiety disorder; Substance use disorder; Significant heart disease (i.e., stroke occurring during 5 years prior to study assessment or cardiac disease non-stabilized with medication); Severe Depression, or a Geriatric Depression Scale (GDS) score greater than 12; Current insomnia disorder
- Current medications for sleep problems, or use of medications that affect sleep
- Use of antidepressant and anti-anxiety medication for less than 3 months prior to study entry
- Use of antipsychotic medication (past or current)
- Having undergone brain surgery or ECT
- Cholesterol or hypertension medication for less than 3 months or changes expected within the next 9 months
- History or presence of neurological or psychiatric disorders (other than MCI) that in the opinion of the investigator may compromise patient safety or study objectives
- Current severe medical conditions (e.g. untreated diabetes, cancer) that in the opinion of the investigator may compromise patient safety or study objectives
- Presence of any medical or psychological condition that, in the opinion of the principal investigator, may compromise the study objectives
- Use of analgesics with codeine (or other opioids)
- Self-reported colour-blindness
- General anesthesia in the past year
- Current smoker
- Suspected or confirmed traumatic brain injury during the last 24 months
- Motion sickness or intolerant to virtual reality tasks
- For female participants, severe menopausal symptoms, including hot flashes (determined from the Greene climacteric scale - any participants scoring over 15 is excluded)
- Use of computer games that are designed to help with memory or general cognition
- Presence of contra-indications for MRI scanning
This trial is currently available in Canada.
It has sites in one country. Choose a country to see its sites.
About the trial
What the trial wants to find out
Mild cognitive impairment (MCI) is often considered a transitional stage between normal aging and dementia, particularly Alzheimer's disease (AD). Patients with MCI have subjective memory complaints corroborated by standard neuropsychological tests but remain functionally autonomous. One of the first brain regions to show AD pathology is the hippocampus (HPC). Reduction in HPC volume is a strong predictor of AD dementia. Therefore, improvement or restoration of HPC structure and function is thus an attractive target for improvement in memory and AD prevention strategies. In the current study, the investigators propose to examine the effects of a 3-month long spatial memory program on spatial memory and the hippocampus in patients diagnosed with MCI. Neuropsychological tests are also administered before and after the training to assess the effects of the intervention on cognition. In our previous research, the investigators have shown that spatial memory intervention program (SMIP) improves cognition and hippocampal based spatial memory compared to controls.
The 2 groups in the trial
- SMIPTreatment being tested
Spatial Memory Intervention Program
- ControlPlacebo, for comparison
The control group will receive no intervention between baseline and follow-up.
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorData and sources
- Registry record
- Listed on ClinicalTrials.gov.How to verify a trial in the registry
- Official title
- Spatial Memory Training and Cognitive Function
- Plain-language title
- Spatial memory training for people with mild cognitive impairmentGenerated from the registry record. The registry title is the official one.
- AI summary
- From the trial's eligibility criteria. Read by machine on 15 November 2026.
- Record updated
- 23 July 2025